Phase 1 Cardiomyopathy Trial, Recruiting NCT07479641 Sponsor: Shandong Suncadia Medicine Co., Ltd. Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 1 Cardiomyopathy Trial, Recruiting

NCT07479641
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 55 years old (inclusive), of any gender
  • Your Body Mass Index (BMI) is between 19 and 28, your weight is between 50 kg and under 90 kg (if male), or between 45 kg and under 90 kg (if female)
  • A full physical examination and lab tests show no significant health concerns, or only minor findings that the study doctor considers acceptable
  • Your heart tracing (ECG) shows no significant abnormalities
  • You understand what the study involves, are willing to take part, and can sign a consent form

Who may not be able to join:

  • You have a known or suspected allergy to the study drug or any of its ingredients
  • You have a history of fainting (syncope)
  • Your blood pressure readings are outside the acceptable range (too high or too low), and the study doctor considers this significant
  • You have had stomach or intestinal surgery that the study doctor thinks could affect how your body absorbs medicines
  • You tested positive for hepatitis B, hepatitis C, syphilis, or HIV during screening
  • You have smoked more than 5 cigarettes a day on average in the 4 weeks before screening
  • You have drunk more than the equivalent of about 450 mL of beer (or 150 mL of wine, or 50 mL of spirits) per day on average in the week before screening
  • You are unwilling or unable to avoid smoking, alcohol, and caffeine-containing food or drinks throughout the study period
  • You have special dietary needs, cannot follow the standardised meals provided in the study, or have a history of substance abuse
  • You have taken any prescription medicines, over-the-counter medicines, or herbal medicines within 1 month before dosing, or within 5 half-lives of any drug before screening (whichever period is longer), or you plan to take any non-study medicines during the trial
  • The study doctor feels, for any other reason, that taking part would not be appropriate or safe for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
14 April 2026
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Peak concentration (Cmax).; Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).; Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov